Restoring p16INK4A expression in DFBM-Ni17 removes the need for CDK4/6 inhibitor to induce tumor response, so that tumors responded to tucatinib alone in the presence of p16INK4A expression (Fig. 3e). This evidence concerns the gene CDK4 and neoplasm.